660

N

End exon 16

661

I

662

K

663

T

664

E

665

E

666

I

667

S

668

E

669

V

670

K

N swedish

671

M

b (BACE)

L swedish

D

1

CTF99

6E10--->

673

A

2

674

E

3

675

F

4

W02->

676

R

5

677

H

6

678

D

7

679

S

8

680

G

9

681

Y

10

->WO2

682

E

11

b'cleavage

683

V

12

684

H

13

685

H

14

686

Q

15

687

K

16

K/L alpha

cleavage

(Adam10,

plasmin

688

L

17

CTF88

----->6E10

4G8--->

689

V

18

690

F

19

691

F

20

692

A

21

G Flemish

Amyloid angiopathy

693

E

22

Q Dutch

G Artic

K

Amyloid angiopathy

694

D

23

N Iowa

Amyloid angiopathy

695

V

24

--->4G8

696

G

25

697

S

26

698

N

27

699

K

28

700

G

29

Membrane

701

A

30

702

I

31

703

I

32

704

G

33

705

L

34

Ann Neurol

2005 Oct;58(4)

pp 639-44

Amyloid angiopathy

M

35

707

V

36

708

G

37

709

G

38

710

V

39

711

V

40

712

I

41

713

A

42

T

Austrian

mutation

714

T

43

I/A

Iran

mutation

715

V

44

M French

 Belgian

mutation

716

I

45

V Florida

mutation

717

V

46

F/G/I

 London

mutation

718

I

47

719

T

48

720

L

49

gamma

cleavage

721

V

 CTF51

722

M

723

L

P Australian

mutation

Membrane

724

K

725

K

650 (APP695)

726

K

727

Q

728

Y

729

T

730

S

731

I

732

H

733

H

734

G

735

V

660

736

V

737

E

738

V

739

D

664

C31.......>

740

A

741

A

742

V

Interaction

743

T

668

phosphorylated

Antibody 

APP-668P

with

744

P

14.3.3gamma

745

E

670

for

746

E

Fe65

747

R

transactivation

748

H

749

L

750

S

751

K

752

M

753

Q

754

Q

755

N

680

756

G

757

Y

758

E

759

N

760

P

761

T

762

Y

763

K

764

F

765

F

690

766

E

767

Q

768

M

769

Q

770

N

695

Carboxy terminal